EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CXCR4-targeted therapy in lung cancer: plerixafor as a promising antimetastatic agent

Prasanna Srinivasan Ramalingam, Muhammad Afzal, M Arockia Babu, Manjunath Mirle Rekha, Samir Sahoo, Surya Nath Pandey, Kavita Goyal, Md Sadique Hussain, Gaurav Gupta, Purushothaman Balakrishnan, Sivakumar Arumugam

Frontiers in Pharmacology · 26.11.2025 · 16

DOI: 10.3389/fphar.2025.1683585 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 26.11.2025. Verfasst von Prasanna Srinivasan Ramalingam und 10 weiteren Autor:innen. Beteiligte Einrichtung: Protein Engineering Lab, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 185 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastasis remains the prime cause of poor prognosis in lung cancer, a leading cause of cancer-related mortality worldwide. Because CXCR4/CXCL12 constitutes a powerful therapeutic target to counter tumor progression, immune evasion, and therapy resistance, it plays a pivotal role in lung cancer. Expression of CXCR4 is high in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and has been correlated with aggressive tumor behavior increased metastatic spread to the bone marrow, the liver, and the brain, and poor overall survival. Studies in preclinical models have demonstrated that plerixafor is a CXCR4 inhibitor that can reduce tumor cell migration, increase chemosensitivity, and re-establish immune response to limit metastasis and increase treatment efficacy. Furthermore, clinical trials combining plerixafor with chemotherapy as well as immune checkpoint inhibitors in NSCLC patients demonstrate that this drug increases T cell infiltration, increases the ability of the tumor to stimulate anti-tumor immunity, and increases progression-free survival. However, although there are promising preclinical and encouraging early clinical data, it is important to address several issues before CXCR4-targeted therapies can become an integral part of lung cancer treatment. They include tumor heterogeneity, adaptive resistance mechanisms, as well as the complexity in the tumor microenvironment of CXCR4 signaling. Additionally, drug development strategies aimed at suppressing CXCR4-driven immune suppression and radioresistance must be combined with chemotherapy, radiotherapy, and immunotherapy therapies to maximize therapeutic benefits. Imaging of CXCR4 with specific PET and the selection of patients on CXCR4 biomarker criteria offer the possibility of further improving precision medicine approaches so that CXCR4-targeted therapies will only be given to the most CXCR4-responsive patients. The role of CXCR4 in lung cancer pathogenesis and development is critically reviewed, the most recent results on plerixafor inhibition of CXCR4 are summarized, and new, potential strategies for combination treatment of CXCR4 with other inhibitors are explored.

Schlagwörter

Stichwörter der Autor:innen

CXCR4immune cell migrationlung cancermetastasisplerixaforprognosistumor microenvironment (TME)tumor progression

Autor:innen und Institutionen

  • Protein Engineering Lab, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
  • Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, Jeddah, Saudi Arabia.
  • Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.
  • Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to Be University), Bengaluru, Karnataka, India.
  • Deptartment of General Medicine, IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, India.
  • Deptartment of Pharmacology, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India.

Zitieren

APA

Ramalingam, P. S., Afzal, M., Babu, M. A., Rekha, M. M., Sahoo, S., Pandey, S. N., Goyal, K., Hussain, M. S., Gupta, G., Balakrishnan, P., & Arumugam, S. (2025). CXCR4-targeted therapy in lung cancer: plerixafor as a promising antimetastatic agent. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1683585

Vancouver

Ramalingam PS, Afzal M, Babu MA, Rekha MM, Sahoo S, Pandey SN, et al. CXCR4-targeted therapy in lung cancer: plerixafor as a promising antimetastatic agent. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1683585

BibTeX
@article{Ramalingam2025,
  author = {Ramalingam, Prasanna Srinivasan and Afzal, Muhammad and Babu, M Arockia and Rekha, Manjunath Mirle and Sahoo, Samir and Pandey, Surya Nath and Goyal, Kavita and Hussain, Md Sadique and Gupta, Gaurav and Balakrishnan, Purushothaman and Arumugam, Sivakumar},
  title = {CXCR4-targeted therapy in lung cancer: plerixafor as a promising antimetastatic agent},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1683585}
}
Kostenlos starten →